Today: 29 April 2026
Browse Category

Biotechnology 3 October 2025 - 16 October 2025

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis shares soared nearly 180% premarket Oct. 16 after positive Phase 3 results for ulixacaltamide in essential tremor, hitting a new 52-week high. The drug met all primary and secondary endpoints in two trials and showed no serious safety issues. Praxis plans to seek FDA approval by early 2026. The company reported a Q2 net loss of $71.1M but held $446M in cash at mid-2025.
16 October 2025
··
Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Sana Biotechnology shares jumped 26% to $5.62 on Oct. 15 after hedge fund manager Eric Jackson called the stock a potential “100-bagger” on X, triggering volatility halts. The rally followed early trial results showing transplanted pancreatic cells produced insulin without immunosuppressive drugs. Sana raised $105 million in summer 2025, extending its cash runway into late 2026. Analyst ratings remain mixed, with targets ranging from $5 to $12.
16 October 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Omeros shares soared 150% to $10.42 on Oct. 15 after Novo Nordisk agreed to license its drug zaltenibart (OMS906) for $340 million upfront and up to $2.1 billion in milestones and royalties. Trading volume hit 89.2 million shares, far above average. Omeros reported a Q2 net loss of $25.4 million and $28.7 million in cash as of June 30. Its lead asset narsoplimab remains under FDA and EMA review.
16 October 2025
···
Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Sana Biotechnology shares jumped 26% to $5.62 on Oct. 15 after hedge fund manager Eric Jackson called the stock “the next 100-bagger” on social media. Trading was briefly halted during the surge. The company recently reported positive diabetes cell-therapy trial data and raised $105 million, extending its cash runway into late 2026. Analyst price targets range from $5 to $12, with a consensus near $7.50.
15 October 2025
··
Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion Pharmaceuticals’ stock jumped about 16% to $6.08 on Oct. 8, 2025, after renewed interest in its AI-driven drug discovery platform. The company reported Q2 revenue of $19.2 million and a net loss of $171.9 million, ending the quarter with $534 million in cash. Management cut 20% of staff in mid-2025 to reduce costs. Analyst targets average $6.50, with mixed ratings.
15 October 2025
···
Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech (NASDAQ: SEED) surged 92% in after-hours trading on Oct. 14, then fell back near $1.43 by Oct. 15. The Beijing agri-tech firm re-entered Northeast China, showcased new hybrid corn seeds, and announced a partnership with Fengtian Seed Industry. CEO Weibin Yan invested $2.4 million in September, with institutions adding $1.48 million. The stock spike followed U.S.-China trade tensions that lifted agriculture shares.
15 October 2025
·
Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion shares jumped 25% on Oct 14, closing at $7.84, after Merck exercised its option on the EVX-B3 vaccine, paying $7.5 million upfront with up to $592 million in milestones. Evaxion will present two-year Phase 2 data for its AI-designed melanoma vaccine at ESMO on Oct 17. The company also announced an upgrade to its AI-Immunology platform and maintains a “Strong Buy” rating from analysts.
15 October 2025
···
Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

Arcadia Biosciences (RKDA) stock soared 68% pre-market Oct 15 to $6.22 after President Trump tweeted about ending some cooking-oil trade with China, sparking a sector rally. The company’s Q2 revenue rose 11% to $1.455 million, all from Zola coconut water, but it posted a $4.46 million net loss due to a $4.5 million write-off on a note from Above Food. The planned merger with Roosevelt Resources remains pending.
15 October 2025
···
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex shares surged 41% after hours on Oct 14, 2025, to $0.36 following new data on its lead cancer therapy. The stock closed regular trading up 30% at $0.25, with volume spiking to 15 million shares. Market cap reached about $11 million. The company’s REQORSA gene therapy is in Phase 2 trials for lung cancer, with new preclinical data set for release at an upcoming oncology conference.
15 October 2025
···
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

NTLA surged past $26 on Oct. 8, 2025, after positive Phase 1 data for its ATTR program showed sustained TTR protein knockdown and no new safety issues. Trading volume spiked to 17 million shares. Wall Street remains bullish, with most analysts rating NTLA a Buy and targets averaging $31.7. Intellia holds $630–707 million in cash and expects funding to last into 2027.
9 October 2025
··
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna closed at $27.34 on Oct 7, 2025, with a market cap near $11 billion. Q2 revenue fell 41% year-over-year to $142 million, and the company posted a net loss of $0.8 billion. U.S. and EU regulators limited updated COVID booster use, narrowing near-term revenue prospects. Analysts’ 12-month price targets remain high, but sales forecasts have repeatedly missed expectations.
8 October 2025
··
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Intellia shares surged to $26.14 on Oct. 8, up 72.6% over the past month, after Phase 1 data showed its CRISPR therapy reduced serum TTR by 92% at 24 months. The company reported Q2 revenue of $14.2 million and a narrowed net loss per share of $0.98. Cash reserves stood at $630 million. Analyst consensus rates the stock a “Moderate Buy” with targets averaging $27–34.
8 October 2025
··
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics (NASDAQ: CRSP) closed at $77.73 on Oct. 8, 2025, up 10% for the day and nearly 20% for the month. Trading volume reached 3.1 million shares, with the price moving between $70.77 and $78.38. The company’s market cap stood at $6.2 billion, and analysts’ average one-year price target was $81. CRSP remains pre-profit, reporting a Q2 net loss of $208.5 million on $0.9 million in revenue.
8 October 2025
·
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia’s NTLA-2001 gene editing therapy cut TTR protein by about 90% for three years in transthyretin amyloidosis patients, with improved outcomes and no new safety issues, according to data presented Sept. 25 and published in NEJM. Enrollment finished for the Phase 3 HAELO trial of NTLA-2002, with top-line results expected in 1H 2026. Intellia stock is up over 60% in 2025. Q2 revenue more than doubled to $14.25 million.
8 October 2025
···
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharmaceuticals’ stock jumped 16% to $6.08 on October 8, 2025, after falling over 5% the previous day. The company uses AI to accelerate drug discovery and recently reported Q2 revenue of $19.2 million, up 33% year-over-year, but posted a net loss of $171.9 million. Recursion holds about $534 million in cash. Recent moves include acquiring Exscientia and cutting several pipeline programs.
8 October 2025
···
No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

Regencell Bioscience shares soared over 64,000% in 2025, peaking at $83.60 before plunging 74% to around $17–18 by October, with a market cap near $8.5 billion. The stock jumped again in early October after S&P Global BMI Index inclusion and positive Phase II trial data showing a 37% improvement in ADHD/ASD symptoms. Regencell remains unprofitable with no revenue. Analysts maintain a “Strong Sell” rating.
7 October 2025
··
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences shares soared over 1,300% after the FDA granted breakthrough therapy designation to its lead drug for Sanfilippo Syndrome Type B. Trading was repeatedly halted amid a flood of investor interest, including public backing from Martin Shkreli. The company, recently relisted on Nasdaq, faces ongoing financial strain with just $16.4 million in cash and no significant revenue.
7 October 2025
··
Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus (NASDAQ:TARS) surged 10.9% to $65.17 on Oct. 3, 2025, after reporting Q2 net product revenue of $102.7 million, up 152% year-over-year, driven by XDEMVY eyedrop sales. Shares have climbed 31% in the past month and 84% over the year. Wall Street consensus rates the stock a “Buy,” with average 12-month targets near $71. Losses are narrowing as sales rise and cash reserves remain strong.
3 October 2025
···
1 … 13 14 15 16

Stock Market Today

  • Micron Technology Stock Outlook to 2030 Amid Soaring AI Memory Demand
    April 28, 2026, 9:37 PM EDT. Micron Technology (MU) has surged 522% in the past year, driven by booming demand for memory chips crucial for AI data centers. The company produces DRAM and NAND flash memory, essential for AI processors handling complex workloads. Industry forecasts suggest a persistent supply shortage through 2030, with data centers expected to consume 70% of global memory production this year. This tight supply-demand balance, supported by limited new factory capacity, positions Micron for sustained growth. Analysts anticipate continued earnings expansion, with fiscal 2025 EPS at $8.29 and potential dips in 2028 viewed as unlikely. Micron's strong footing in the red-hot AI memory market could enable further stock gains by the decade's end.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop